EntreMed to Present at the BIO 2007 Investor Forum
ROCKVILLE, MD â€“ October 4, 2007 â€“ EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Biotechnology Industry Organization 2007 Investor Forum, being held at the Palace Hotel, San Francisco, California, October 9-11, 2007. Mr. Burnsâ€™ presentation is scheduled for Wednesday, October 10, 2007, at 3:15 p.m. (Pacific time).
Mr. Burnsâ€™ live presentation will be web cast and can be accessed through the Companyâ€™s web site at www.entremed.com. An archive will be available on the web site for approximately 90 days.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. PanzemÂ® is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell-cycle regulation and inflammation â€“ processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Companyâ€™s web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
CASI Pharmaceuticals, Inc.